

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/002588

A. CLASSIFICATION OF SUBJECT MATTER

G01N33/68	C12Q1/68	A61P25/00	C07K14/71	G01N33/574
A61P35/00	A61P29/00	A61P11/00	A61K39/395	A61K38/00
A61K47/46	A61K31/70			

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N G01N C12Q A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, Sequence Search, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/43081 A (LIGAND PHARMACEUTICALS INCORPORATED; INSTITUT PASTEUR; LEFEBVRE, ANNE-) 1 October 1998 (1998-10-01) the whole document, see especially p. 7-10 and 14-16	1-17, 19-26
Y	-----	18
X	WO 2004/006662 A (TAKEDA CHEMICAL INDUSTRIES, LTD; AMANO, YUICHIRO; SUGIYAMA, YASUO; NIS) 22 January 2004 (2004-01-22) the whole document	1-11, 19-21, 24-26
Y	-----	12-18
X	& EP 1 535 512 A (TAKEDA PHARMACEUTICAL COMPANY LIMITED) 1 June 2005 (2005-06-01)	1-11, 19-21, 24-26
Y	the whole document, see especially paragraphs 11-16, 76-80, 86-88.	12-18

		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

3 September 2005

Date of mailing of the international search report

01.12.2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

STEINHEIMER, K

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/002588

BEST AVAILABLE COPY

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 392 386 A (* CXR BIOSCIENCES LIMITED) 3 March 2004 (2004-03-03) the whole document, see especially p. 13-14 -----	1-10, 19-21, 24-26
X	WO 02/064632 A (SMITHKLINE BEECHAM CORPORATION; LAMBERT, MILLARD, HURST, III; MONTANA,) 22 August 2002 (2002-08-22) the whole document, see especially p. 59-60 -----	1-10, 19-21, 24-26
X	WO 99/18124 A (MERCK & CO., INC; CUMMINGS, RICHARD, T; HERMES, JEFFREY, D; MOLLER, DA) 15 April 1999 (1999-04-15) page 1 - page 19 -----	1-11, 19-21, 24-26
X	WO 03/062427 A (YAMANOUCHI PHARMACEUTICAL CO., LTD; ENDOH, HIDEKI; NAKANO, RYOSUKE; KU) 31 July 2003 (2003-07-31) the whole document -----	1-17, 19-21, 24-26
X	& EP 1 469 071 A (YAMANOUCHI PHARMACEUTICAL CO. LTD) 20 October 2004 (2004-10-20) paragraph [0035] - paragraph [0064] -----	1-17, 19-21, 24-26
X	US 6 544 743 B1 (HUDSON THOMAS J ET AL) 8 April 2003 (2003-04-08) cited in the application -----	22,23
Y	paragraph [0074] - paragraph [0120] -----	18
X	WO 95/11974 A (LIGAND PHARMACEUTICALS, INC) 4 May 1995 (1995-05-04) paragraph [0078] - paragraph [0120] -----	22,23
Y	-----	12-18
X	WO 01/20037 A (COMPLEXE HOSPITALIER DE LA SAGAMIE; MCGILL UNIVERSITY; HUDSON, THOMAS,) 22 March 2001 (2001-03-22) cited in the application page 8 -----	19-26
X	TANAKA TAKUJI ET AL: "Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats" 15 March 2001 (2001-03-15), CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, PAGE(S) 2424-2428 , XP002247794 ISSN: 0008-5472 page 2424 -----	19-21,24
	-----	-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/002588

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 380 562 A (EISAI CO., LTD) 14 January 2004 (2004-01-14) paragraph [0001] - paragraph [0026] -----	19-21, 24-26
P,X	US 2004/115637 A1 (MCKAY ROBERT ET AL) 17 June 2004 (2004-06-17) the whole document, see especially paragraphs 24, 56 and 70 -----	19-21, 24-26

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/002588

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-26 (partial)

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-26 (partial)

These claims concern methods which involve a PPARA for screening for therapeutic agents useful in the treatment of gastroenterological diseases (claims 1-17), a method for diagnosing said diseases (claim 18), pharmaceutical compositions for treatment of said diseases (claims 19-23) or use of regulators of a PPARA for the preparation of a pharmaceutical composition for the treatment of said diseases (claim 24), a method for the preparation of a pharmaceutical composition useful for the treatment of said diseases (claim 25) or use of a regulator of PPARA for the regulation of the activity of PPARA in a mammal having the said diseases.

2. claims: 1-26 (partial)

These claims concern methods which involve PPARA as a screening marker/diagnostic marker/therapeutical target (see above) in conjunction with cancer.

3. claims: 1-26 (partial)

These claims concern methods which involve PPARA as a screening marker/diagnostic marker/therapeutical target (see above) in conjunction with inflammation.

4. claims: claims 1-26 (partial)

These claims concern methods which involve PPARA as a screening marker/diagnostic marker/therapeutical target (see above) in conjunction with neurological diseases.

BEST AVAILABLE COPY